Evidence map›Paper›PMID 37759784›Full record

ArticleBiomolecules2023

Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren's Syndrome.

Vanessa Bianconi, Giacomo Cafaro, Massimo Raffaele Mannarino, Carlo Perricone, Elena Cosentini, Onelia Bistoni, Rita Paltriccia, Rita Lombardini, Roberto Gerli, Matteo Pirro and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Sjogren's Disease and Elevated Cardiovascular Risk: Mechanisms and Treatment.Journal of cardiovascular development and disease · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Vanessa BianconiUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
Giacomo CafaroRheumatology Unit, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.ORCID 0000-0003-1774-1916
Massimo Raffaele MannarinoUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.ORCID 0000-0003-4694-5504
Carlo PerriconeRheumatology Unit, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.ORCID 0000-0003-4771-6981
Elena CosentiniUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
Onelia BistoniRheumatology Unit, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
Rita PaltricciaUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
Rita LombardiniUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.ORCID 0000-0001-7682-9817
Roberto GerliRheumatology Unit, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
Matteo PirroUnit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
Elena BartoloniRheumatology Unit, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.ORCID 0000-0003-4776-2136
University of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism contributing to cardiovascular (CV) risk in the general population. The relationship between PCSK9 and CV risk in systemic autoimmune diseases has been poorly explored. We investigated the association between plasma PCSK9, measures of immune-inflammatory status and markers of atherosclerosis in 52 consecutive patients with primary Sjögren's syndrome (pSS) in comparison to healthy controls (HCs). Median plasma PCSK9 levels were significantly higher in pSS patients versus HCs (162 (79-255) vs. 53 (39-99) ng/mL). Significantly higher prevalence of subclinical atherosclerosis and lower of dyslipidaemia (61% vs. 85%,

Indexed as

AtherosclerosisSjogren's SyndromeHumansLipidsProprotein Convertase 9LipidsPCSK9 protein, humanProprotein Convertase 9atherosclerosiscardiovasculardyslipidemiainflammationPCSK9

Identifiers

PMID37759784
PMCPMC10527459
OpenAlexW4386714845

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.